Insights

It’s not a stretch to say that Corealis has been attending AAPS PharmSci 360 since our beginning. In fact, we may owe our very existence to this event — well, that and a conveniently located Cheesecake Factory. That’s a true story. It was there that...

Believe it or not, 2024 might actually be a record year for pharmaceutical investment, but most of that money is not being directed toward drug discovery. My perspective is this: Many pharmaceutical and biotech venture capitalists are once-bitten,...

We are long past the era when drug development was a convenient byproduct of pure chance. Now, steady innovation tends to require steady capital. But, after 2021, venture capitalists have been understandably hesitant to invest in an industry where...

Not every event in our industry has the same goal, and if you’ve been attending trade shows and conferences like these for quite some time, you know that some prioritize partnership opportunities over content. Those will always present tremendous...

90% of clinical trials fail. That statistic has been passed around so often that it no longer raises eyebrows in our industry, but we believe it should. Frankly, we find this statistic both unacceptable and unnecessary. To be clear, the path to...

Drug development can be an incredibly rewarding journey, which is what has attracted most of us to this industry. Whenever we attend industry events, we find ourselves surrounded by relentless optimists. However, the process can be extraordinarily...

If I were in any other industry, I wouldn't begin a blog discussing the inauguration of new laboratory facilities with some very unnewsworthy observations. But this isn't any other industry. And in ours, completing a complex project on time and on...

CPHI North America is one of the larger events that we attend every year. And while it’s always a tremendous opportunity to connect with colleagues and make new connections, it also presents an incredible opportunity to unite the entire...